Eli Lilly and Camurus Sign $870M Deal for Long-Acting Obesity Therapies
Eli Lilly and Swedish biotech Camurus have entered into a collaboration and license agreement, announced on June 3, 2025, aimed at developing long-acting obesity therapies using Camurus’ FluidCrystal technology and Lilly’s proprietary drug compounds12345.
The partnership grants Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize long-acting incretin products for cardiometabolic health; up to four of Lilly’s drug compounds are included in the deal125.
The agreement could be worth up to $870 million to Camurus, including $290 million in upfront, development, and regulatory milestone payments, an additional $580 million in sales-based milestones, and tiered mid-single-digit royalties on global net product sales15.
The deal focuses on dual and triple agonist therapies, including GIP and GLP-1 receptor agonists, and gives Lilly the option to include amylin receptor agonists5.
The collaboration leverages Camurus’ long-acting depot technology, FluidCrystal, to address growing global needs in obesity, diabetes, and other serious chronic diseases, while Camurus maintains its commercial focus on CNS and rare diseases125.
Sources:
1. https://www.prnewswire.com/news-releases/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins-302472324.html
2. https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/
3. https://www.biopharmadive.com/news/eli-lilly-camarus-long-acting-obesity-drug-deal/749761/
4. https://www.benzinga.com/news/health-care/25/06/45769020/mounjaro-maker-eli-lilly-taps-swedish-firm-camurus-to-target-long-acting-obesity-market-in-870-million-deal
5. https://www.stocktitan.net/news/CAMX/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-2saf79vso2qx.html